Clinical Trial Update: Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial results evaluating the safety and efficacy of AON-D21 in adults with severe community-acquired pneumonia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia

Drugs mentioned

• AON-D21

Snippet

Sponsor: Aptarion Biotech AG | Conditions: Community-acquired Pneumonia | Phase 2 | Status: COMPLETED